Gastroenterology · Medical Literature
[Corrections] Correction to Lancet Gastroenterol Hepatol 2026; 11: 546–49
Abstract
Quraishi MN, Al-Bawardy B, Banerjee R, et al. Breaking the cycle: from documenting data scarcity to enabling global IBD research. Lancet Gastroenterol Hepatol 2026; 11: 546–49—In this Comment, the corresponding author should have been Mohammed Nabil Quraishi. This correction has been made to the online version as of July 8, 2026.
Clinical relevance
Does the existing global IBD research landscape adequately represent data from all world regions, and what strategies can move the field from documenting data scarcity toward enabling inclusive, worldwide IBD research? __SNAPSHOT__ {"studyDesign":"Expert Commentary (narrative opinion piece; not an original research study — no primary data collected, no control group, no statistical analysis)","setting":"Multinational authorship spanning the United Arab Emirates, Saudi Arabia, India, Brazil, South Africa, and Denmark; published in The Lancet Gastroenterology & Hepatology, July 2026","sampleSize":"Not applicable (commentary; no patient-level data)","population":"Not applicable; the commentary addresses the global IBD research community and policy stakeholders broadly, with particular relevance to patients and investigators in low- and middle-income countries (LMICs) and newly industrializing regions","intervention":"Proposed conceptual and structural strategies to transition IBD research from descriptive documentation of data gaps to active enablement of inclusive global research capacity","comparator":"Not applicable","primaryOutcome":"Not applicable; no quantitative primary endpoint defined","followUp":"Not applicable","fundingSource":"Not reported in the abstract. Note: disclosed conflicts of interest for at least two named authors include speaker fees, consultancy fees, and conference travel support from multiple pharmaceutical companies (Johnson & Johnson, Takeda, AbbVie, Hikma, Tillotts, Lilly), and leadership roles in non-profit IBD organizations."}
Key findings
As a published Commentary, this article presents no original empirical data, effect sizes, p-values, confidence intervals, or NNT/NNH values — none are reported and none are calculable. The piece argues that existing IBD research is heavily concentrated in high-income countries and fails to reflect the rapidly rising burden in LMICs across Asia, Africa, and Latin America. The authors contend that the field must move beyond cataloguing data deficits to actively building research infrastructure, data-sharing frameworks, and investigator capacity in underrepresented regions. No quantitative outcomes, adverse events, or statistical findings are associated with this work.
Practice implications
This is an expert opinion commentary, not an original research study; therefore, its conclusions do not constitute Level I or II evidence and should not be interpreted as such. The piece does not establish causality, efficacy of any intervention, or clinical outcomes for individual patients. Its relevance to practicing clinicians lies in contextualizing why evidence generated predominantly from high-income country cohorts may not be generalizable to patients from South Asia, sub-Saharan Africa, Latin America, or the Middle East — regions experiencing accelerating IBD incidence in settings with distinct environmental exposures, genetic backgrounds, and healthcare infrastructure. Clinicians managing patients from these backgrounds should be aware that current treatment guidelines and epidemiological estimates are largely extrapolated from populations that may not represent their patients. The commentary's recommendations are directed primarily at researchers, funders, and policymakers. Only the online version has been corrected (as of July 8, 2026) to properly identify Mohammed Nabil Quraishi as the corresponding author; this correction carries no implications for the clinical content. Because only a correction notice was available as the submitted abstract — not the full text of the original Commentary — this summary is necessarily limited in its ability to characterize the authors' specific proposed solutions. __LIMITATIONS__ 1. Study design: Expert commentary; represents the lowest tier of evidence hierarchy. No primary data, no hypothesis testing, no control comparisons. 2. Potential bias: Authors include individuals with financial relationships with pharmaceutical industry stakeholders, which may influence the framing of priorities. 3. Scope of abstract: The submitted input is a correction notice only, not the original Commentary abstract or full text; the totality of the authors' arguments, evidence base, and recommendations cannot be fully evaluated. 4. Generalizability of proposed solutions: Not empirically tested; feasibility and impact of recommended strategies are undemonstrated. 5. Authorship correction: The published correction addresses only the misidentification of the corresponding author and has no bearing on scientific content. 6. No patient-centered outcomes: The piece does not report on clinical endpoints, safety signals, or treatment effects relevant to individual patient management. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This expert commentary highlights a recognized structural gap in global IBD research — the underrepresentation of data from LMICs — and calls for actionable steps to build inclusive research capacity; however, it provides no original empirical data to support specific recommendations. Clinicians should recognize that current IBD evidence bases may have limited generalizability to patients from rapidly industrializing regions. The published correction pertains solely to authorship attribution (corresponding author designation) and does not alter the scientific content.